The pharmaceutical sector grew robustly in the third quarter of FY25 driven by multiple factors. The same can be seen in the pharma industry Q3 results as most of the pharma companies did well in the quarter and most of it has been driven by factors like new medicines getting introduced in the market, domestic formulations witnessed a huge growth, especially in the areas like gastrointestinal issues, cardiac and diabetic issues. The shortage of drugs in the US market also helped boost sales in the Indian pharma market. These reasons pushed the overall sector forward, as depicted by the pharmaceutical industry Q3 results.
In this article, we will be talking about ten pharmaceutical companies which have announced their Q3 results recently.
Top Ten Q3 Results – Pharma Sector
- Lupin: On February 11, Lupin announced its third-quarter results which showed a rise of 10% YoY in the revenue for the period from ₹5768 crore to ₹5197 crore. The Net profit for the period went up from ₹619 crore to ₹859 crore registering a 38% growth YoY.
- Alkem Lab: This pharma giant witnessed a nominal growth of 1% in the revenue during FY25’s third quarter compared to the previous fiscal’s corresponding quarter while its net profit went up from ₹604 crore to ₹641 crore which is a 6% rise.
- Aurobindo Pharma: This is one of the most popular pharmaceutical stocks but the company witnessed a decrease in its profits (net profit) during Q3FY25. The profit tanked by 10% during the quarter while the revenue witnessed an 8% rise from Rs,7352 crore in Q3FY24 to ₹7979 crore in this oct-dec quarter.
- Zydus Life: This pharma giant witnessed a whopping 16% rise in its revenue YoY from ₹4505 crore back in Q3FY24 to ₹5269 crore in this fiscal quarter. The firm also witnessed a 27% rise in gross profit and a 36% rise in net profit as well depicting the strong demand for its products.
- Divis Lab: With a rise of 25% in revenue, this pharma company churned out a 64% rise in the net profit in Q3FY25 compared to Q3FY24. The revenue rose from ₹1855 crore in Q3FY24 to ₹2319 crore in this quarter ended on 31 December 2024. The Net profit went up from ₹358 crore in the corresponding quarter last fiscal to ₹589 crore.
- Sun Pharma: In the pharma sector, this is one of the biggest pharmaceutical companies shares and the company witnessed a 13% surge in the net profit and an 18% surge in the gross profit. The revenue grew 10% YoY from ₹12381 crores to ₹13675 crore in Q3FY24 and Q3FY25 respectively.
- Cipla: Another pharma giant which saw a 48% rise in its net profit during the third quarter of FY25. The net profit jumped from ₹1069 crore to ₹1584 crore in Q3FY25. While the net profit surged so high, it has been driven by only 7% growth in the revenue which indicates management’s efficiency in optimizing profits.
- Torrent Pharma: This pharma company witnessed 13% in the net profit for the December quarter compared to the corresponding quarter last fiscal. The revenue only went up by 2% from ₹2732 crore to ₹2809 crore.
- Mankind Pharma: This firm witnessed a decrease in the net profit by 14% even when its gross profit surged by 27% and revenue by 1%. The external and other factors played here to drag the actual profit.
- Dr. Reddy’s Labs: This pharma firm witnessed a 15% rise in revenue during the December quarter but its net profit only rose by 1% during the same period. The net profit went up from ₹1378 crore to ₹1400 crore only.
Wrapping up
While the market witnessed robust growth in the third quarter, challenges are there such as pricing pressure, excessive competition, and other factors which need to be overcome to sustain the Indian pharma market growth.
Source: MoneyControl
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.